Completed PHASE2 INTERVENTIONAL NCT00003131

CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse

Sponsor: Pfizer

Conditions Leukemia

Interventions chemotherapy gemtuzumab ozogamicin

Updated 5 times since 2017 Last updated: Aug 21, 2012 Started: Feb 28, 1997 Primary completion: Feb 28, 2002 Completion: Feb 28, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003131, this PHASE2 trial focuses on Leukemia and remains completed. Sponsored by Pfizer, it has been updated 5 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Boston, United States , Chicago, United States , Duarte, United States , Houston, United States , Miami, United States , New Hyde Park, United States , New York, United States , Omaha, United States and 3 more locations